SafePolyMed
Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions
- Description
Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increase healthcare costs. ADRs are among the leading causes of death in developed countries and a major cause of hospitalization. Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are highly interconnected and require a holistic approach to improve safety of our citizens. However, investigations on real-life drug-drug-gene interactions (DDGIs) in clinical trials are unfeasible due to combinatorial explosion, high costs and ethical concerns. Hence, significant knowledge gaps exist. Furthermore, the lack of participation in managing their conditions might be excessively demanding for polymedicated and multimorbid citizens.
Bringing together 12 partners from across Europe, SafePolyMed will develop a novel and innovative framework to define, assess and manage DDGIs for physicians and individual patients resulting in education and empowerment of citizens as well as in reduced healthcare costs by improving patient safety.
- Coordinator
- Prof. Dr Thorsten LehrUniversität des SaarlandesPhone: +49 681 302 70255
- Programme
- Horizon Europe & sub-programmes
- Duration
- 42 months (July 2022 - December 2025)
- Project funding
- € 5,650,442.81
- Project partners
- 12
- Project website
- https://www.safepolymed.eu/
